HIV/AIDS Therapeutics and Diagnostics Markets Hampered by Economic and Social Malaise
New market research study released today clearly paints a picture of the disparity between the theoretical and realistic markets for HIV/AIDS therapeutics and diagnostics.
New York (PRWEB) March 18, 2006
Assessing the long term epidemiology of global HIV/AIDS, new research released today clearly paints a picture of the disparity between the theoretical and realistic markets for HIV/AIDS therapeutics and diagnostics.
According to HIV: A Strategic Analysis of Therapeutic and Testing Markets, a new study from market research firm Kalorama Information, current societal and ethical pressures, geopolitical factors, marketplace disruptions, and economic instability are continually eroding global markets, particularly those in which the need for HIV/AIDS treatments is gravest.
Kalorama Information, a division of MarketResearch. com, a leading provider of industry-specific market research reports, estimates that the market potential for therapeutics in Sub-Saharan Africa alone could potentially be $310 billion based on current prevalence and incidence of HIV in both adults and children. However, based on current economies, which are incapable of paying for their populations’ healthcare needs, the realistic potential is estimated at $1.4 billion.
Other hot spots, such as the Caribbean, Eastern Europe—particularly Russia where the situation is critical—and North Africa and the Middle East—where regional attitudes contribute to an unwillingness to address the problem—face similar problems which create an extremely challenging environment in which to introduce potentially advantageous HIV/AIDS solutions.
“There’s a strategic interplay between HIV/AIDS diagnostics and therapeutics that is one of the most complex ever experienced in the healthcare industry,” notes Kenneth G. Krul, Ph. D., the report’s author. “In order to develop a coherent strategy for success and profit in this area, companies must focus not only on market potential, but on the epidemiology and current/emerging technologies in order to allocate resources in the right areas.”
A detailed epidemiological assessment on a regional level, this study focuses on the policy aspects of HIV/AIDS, the factors associated with strategic market development of HIV/AIDS diagnostics and therapeutics, and prospects for the future.
HIV: A Strategic Analysis of Therapeutic and Testing Markets provides an informative picture of potential market advances in the world of HIV/AIDS and can be purchased directly from Kalorama Information by clicking http://www. kaloramainformation. com/pub/1189531.html (http://www. kaloramainformation. com/pub/1189531.html). It is also available at MarketResearch. com.
About Kalorama Information
Kalorama Information, a division of MarketResearch. com, supplies the latest in independent market research for the life sciences. For more information, contact Tom Ehart at 240-747-3014 or tehart@marketresearch. com, or visit www. KaloramaInformation. com
###
